PARLIAMENT QUESTION: BIO-ECONOMY

1. At a Glance

• Bio-economy = economic activity derived from biological resources, biotech innovation, biomanufacturing (pharma, agri-biotech, bio-industrial, bio-services, bio-IT). [S1]
• India's bio-economy is now a flagship Sci-Tech vertical under DBT, targeted to hit USD 300 billion by 2030; tested under GS-III (S&T, Economy) and Prelims (schemes/policies). [S1]
• Anchored by two recent policy/scheme instruments — BioE3 Policy (Aug 2024) and Bio-RIDE Scheme (Sept 2024). [S2][S3]

2. Why in the News

• 25 March 2026: MoS S&T answered a Parliament question on Bio-economy in the PIB release by Ministry of Science & Technology. [S1]
• 19 March 2026: India Bioeconomy Report 2026 released, pegging the sector at USD 195.3 billion (2025), up from USD 165 bn (2024) — an 18% annual growth rate. [S1]
• DBT and BIRAC announced India's first Biofoundry under Bio-RIDE. [S1]

3. Background & Evolution

• Department of Biotechnology (DBT) set up 1986 under Ministry of Science & Technology — nodal agency. [S1]
• BIRAC — DBT's PSU (a Sec-8 not-for-profit) — drives industry-academia innovation linkage. [S3]
• 24 Aug 2024: Union Cabinet approved BioE3 Policy — India's first dedicated biotech policy for high-performance biomanufacturing. [S2]
• 18 Sept 2024: Cabinet approved Bio-RIDE — merger of two umbrella DBT schemes plus a new biomanufacturing/biofoundry component. [S3]

4. Core Static Facts

• Full form — BioE3: Biotechnology for Economy, Environment & Employment. [S2]
• Full form — Bio-RIDE: Biotechnology Research Innovation and Entrepreneurship Development. [S3]
• Bio-RIDE outlay: Rs 9,197 crore for 15th Finance Commission period (2021-22 to 2025-26). [S3]
• Bio-RIDE 3 components: (i) Biotechnology R&D, (ii) Industrial & Entrepreneurship Development, (iii) Biomanufacturing & Biofoundry (new). [S3]
• Bio-economy target: USD 300 billion by 2030. [S1]
• Bio-economy size: USD 195.3 bn (2025) vs USD 165 bn (2024); 18% YoY growth. [S1]
• Nodal ministry: Ministry of Science & Technology → DBT; PSU arm = BIRAC. [S1][S3]
• BioE3 thematic areas: bio-based chemicals, biopolymers, enzymes, climate-resilient agriculture, smart proteins, carbon capture & utilization, precision biotherapeutics (cell & gene therapy, mRNA, mAbs), marine & space biotech. [S2]

5. Multi-Dimensional Analysis

Economic - Targets ~3× expansion (USD 100 bn → USD 300 bn) by 2030, deepening high-value manufacturing share of GDP. [S1] - Bio-RIDE bridges TRL gap from lab to market via BIRAC-led startup funding. [S3]

Scientific / Technological - BioE3 pivots from import-dependent fermentation/biologics to indigenous biofoundries and Bio-AI hubs ("मूलांकुर" hubs). [S2] - Covers frontier verticals: mRNA, gene therapy, synthetic biology, carbon capture. [S2]

Environmental - Sustainable biomanufacturing aims to substitute fossil-based inputs (biopolymers, bio-chemicals), aligning with Net Zero 2070. [S2] - Climate-resilient agri-biotech included as thematic priority. [S2]

Administrative / Federal - Centre-State BioE3 MoU signed with Assam (2025) — model for state-level rollout. [S2] - Implementation concentrated in DBT/BIRAC; risk of skewed regional cluster distribution.

Geopolitical / Strategic - Reduces dependence on imported APIs and bio-feedstocks; positions India in global bio-supply chains; Minister framed it as India's lead in the "next Industrial Revolution." [S2]

6. Recent Developments (last 12-18 months)

• 24 Aug 2024: BioE3 Policy approved by Cabinet. [S2]
• 18 Sept 2024: Bio-RIDE scheme approved (Rs 9,197 cr). [S3]
• 2025: DBT–Assam MoU under BioE3 — first Centre-State partnership. [S2]
• 2025: DBT-BIRAC joint Bio-AI call for मूलांकुर hubs. [S2]
• 19 Mar 2026: India Bioeconomy Report 2026 released — USD 195.3 bn. [S1]
• 25 Mar 2026: Parliament reply on bio-economy progress. [S1]

7. Prelims Hooks

• Bio-economy 2030 target: USD 300 billion. [S1]
• Bio-economy 2025 size: USD 195.3 billion. [S1]
• Annual growth rate cited: 18%. [S1]
• BioE3 expands to Economy, Environment & Employment — NOT "Energy". [S2]
• BioE3 approved on 24 August 2024 by Union Cabinet. [S2]
• Bio-RIDE approved on 18 September 2024. [S3]
• Bio-RIDE outlay: Rs 9,197 crore (2021-22 to 2025-26). [S3]
• New component added under Bio-RIDE: Biomanufacturing & Biofoundry. [S3]
• Nodal department: DBT, under Ministry of Science & Technology. [S1]
• PSU implementing biotech startup support: BIRAC. [S3]
• BioE3 includes precision biotherapeutics — cell & gene therapy, mRNA, mAbs. [S2]
• "मूलांकुर hubs" are under a Bio-AI joint call by DBT-BIRAC. [S2]
• India Bioeconomy Report 2026 released on 19 March 2026. [S1]
• BioE3 Centre-State MoU first signed with Assam. [S2]

8. Mains Relevance

• GS-III: Science & Technology — developments and applications; Indian Economy — growth, employment.
• Syllabus heads: "Awareness in fields of S&T", "Achievements of Indians in S&T; indigenization", "Inclusive growth".
• Q-stems: 1. "Discuss how the BioE3 Policy and Bio-RIDE scheme together can transform India into a high-performance biomanufacturing hub by 2030." 2. "Bio-economy is increasingly seen as the next frontier of sustainable industrial growth. Examine India's preparedness with respect to policy, finance and human capital." 3. "Evaluate the role of BIRAC in catalysing biotech entrepreneurship in India."

9. Related Topics to Study Next

• National Biotechnology Development Strategy — overarching DBT framework.
• PLI Scheme for Pharmaceuticals & Bulk Drugs — complementary to BioE3 manufacturing thrust.
• GM Crops & GEAC — regulatory dimension of agri-biotech.
• National Quantum Mission / Vigyan Dhara — co-approved Cabinet S&T initiatives.
• Net Zero 2070 & carbon capture — environmental linkage to bio-economy.
• Startup India / Atal Innovation Mission — entrepreneurship ecosystem overlap.
• TRIPS & Patent regime — IPR backbone for biotech innovation.
• One Health approach — biosecurity/biopharma cross-cut.

10. Common Errors / Trap Areas

• BioE3 ≠ Energy; the three E's are Economy, Environment, Employment. [S2]
• Bio-RIDE is a scheme, BioE3 is a policy — distinct instruments approved within weeks of each other. [S2][S3]
• Nodal body is DBT (under MoS&T), not MoEFCC or DSIR.
• BIRAC is a PSU/Sec-8 company under DBT, often confused with an autonomous body.
• Bio-RIDE outlay applies to 15th FC period, not annual.
• Bioeconomy figure of USD 195.3 bn pertains to 2025, not 2024 (Report year 2026). [S1]

11. Sources

• [S1] PARLIAMENT QUESTION: BIO-ECONOMY — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2244972 — (tier: 1)
• [S2] S&T Minister releases BioE3 Policy / Cabinet approval & MoUs — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2050446 ; https://dbtindia.gov.in/news-features/cabinet-approves-bioe3-biotechnology-economy-environment-and-employment-policy ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=2110703 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=2127063 — (tier: 1)
• [S3] Cabinet approves Bio-RIDE scheme — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2056001 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=2244974 — (tier: 1)